StockData
Repligen Corp logo

Repligen Corp (RGEN) stock analysis

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30145% above fair value
$166.52−6.10 (-3.53%)

Close on Nov 12, 2026Market cap $10.64BP/E –Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth3Performance2Health2Dividend0

Weak7 of 30 checks passed

Repligen passes 7 of the 30 checks behind our score; 10 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
3/6
Past performance
2/6
Financial health
2/6
Dividend
0/6

What stands out

  • Low bankruptcy risk

    The Altman Z-score is 8.89; above 3 is the safe zone and below 1.8 the distress zone.

  • Guidance raised

    Repligen raised its FY 2026 Total Reported Revenue outlook on Oct 27, 2026.

  • Growing faster than the industry

    Revenue grew 13.8% over the last twelve months; the Drugs median is 8.0%.

  • Gross margin improving

    Gross margin was 53.5% over the last twelve months, against 45.7% a year earlier.

What to watch

  • Margin of safety under 20%

    The price is 145% above fair value, so there is no margin of safety.

  • Trading above fair value

    The share price of $172.62 is above our fair value estimate of $70.46.

  • Return on equity under 15%

    Return on equity was -0.6% over the last twelve months and averaged 4.2% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was 0.7%, below the 10% that usually covers the cost of capital.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA above its 5-year median

    Repligen's EV/EBITDA of 105.8 is above its 5-year median of 58.7.

  • P/B above the industry

    Repligen's price-to-book of 5.28 is above the Drugs median of 2.29.

  • Trading above fair value

    The share price of $172.62 is above our fair value estimate of $70.46.

  • Margin of safety under 20%

    The price is 145% above fair value, so there is no margin of safety.

Growth3/6

  • Revenue growing under 10% a year

    Revenue grew -2.7% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growing under 10% a year

    Diluted EPS grew -35.7% a year over the last three fiscal years.

  • Earnings growth not accelerating

    Net income grew -779% over the last twelve months, against a 5-year average of -4.0% a year.

  • Growing faster than the industry

    Revenue grew 13.8% over the last twelve months; the Drugs median is 8.0%.

  • Guidance raised

    Repligen raised its FY 2026 Total Reported Revenue outlook on Oct 27, 2026.

  • Gross margin improving

    Gross margin was 53.5% over the last twelve months, against 45.7% a year earlier.

Past performance2/6

  • Return on equity under 15%

    Return on equity was -0.6% over the last twelve months and averaged 4.2% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was 0.7%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Repligen's return on equity of -0.6% is above the Drugs median of -58.9%.

  • Earnings shrank over 5 years

    Net income shrank 4.0% a year on average over the last five fiscal years.

  • Net margin below its 5-year average

    Net margin was -1.5% over the last twelve months, against a 5-year average of 10.1%.

  • Net margin above the industry

    Repligen's net margin of -1.5% is above the Drugs median of -53.0%.

Financial health2/6

  • Debt level

    Needs debt and equity figures.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt coverage

    Needs operating cash flow.

  • Interest not well covered

    Operating income covers interest expense 0.8 times; we look for at least 5.

  • Short-term assets cover short-term debts

    Current assets are 9.88 times current liabilities.

  • Low bankruptcy risk

    The Altman Z-score is 8.89; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Repligen has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

Our estimate per share

$70.46

The share price is 145% above this estimate.

20%+ below
Near fair value
20%+ above
$172.62Price$70.46Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
EV/EBITDA30.0×58.7×17.1×$58.6278%
P/B3.4×4.5×2.3×$111.8922%
Earnings powerleft out, too far from the others12.3% cost of equity––$13.60–
Fair value$70.46100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Drugs median 25.1

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$243.60M
Value traded per 1% price move
$90.27M

Downside

Medium risk

Typical loss in a bad month
19.2%
Volatility (annualized)
47%
Sharpe ratio, 1 year
0.30
Beta to the S&P 500 (5Y)
1.49

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2010 to 2025

Gross margin

52.3%−4.9 pts over 5 years

Operating margin

7.5%−11.6 pts over 5 years

Net margin

6.6%−9.7 pts over 5 years

See a number that looks wrong?